Basic↦Ethics and Laws↦Authorities↦Swissmedic
Was betrifft es? Warum ist das wichtig?
Swissmedic is the Swiss authority regarding the licensing, authorization, and/or monitoring of therapeutic products, including:
- Human medicine
- Veterinary medicine
- Complementary & herbal medicine
- Medical device
Core competencies include to:
- Approve studies. In comparison to the Ethics Committee (EC) Swissmedic only approves higher risk studies (e.g. risk categories B and C), such as:
- Issue licences for the manufacturing of MPs
- Authorise MPs to be sold on the Swiss market
- Inspect studies and their compliance with regulatory requirements and guidelines (e.g. Swiss Law, ICH GCP, ISO 14155)
- Monitor the safety and quality of MPs/MDs in studies and on the open market
- Inspect manufacturing companies to evaluate the quality of MPs/MDs
- Issue information aimed at healthcare professionals and patients
- Cooperate with national and international agencies
Mehr
In comparison to MPs authorisation requirements, MDs do not undergo official Swissmedic authorisation procedures. For devices, Switzerland has taken over the EU system of compliance and assessment certification. The visible result of a compliance assessment is the so-called CE label, which permits medical devices to be placed / sold on the market.
Swissmedic is attached to the Federal Department of Home Affairs.
Was muss ich befolgen?
As a SP-INV, know that whether a study requires a Swissmedic approval (e.g.approval of medicinal product or medical device studies) depends on the risk-category of your study.
Special Swissmedic submission and EC submissions requirements apply, which can be done concurrently. In contrast to a Swissmedic approval, all studies or research projects, irrespective of study risk-category, require an EC approval.
As a SP-INV or Site-INV, keep in mind to notify to Swissmedic any:
- Changes to the conduct if your study (e.g. amendments)
- Changes to the ongoing risk-benefit evaluation
- Other reporting obligations (e.g. first-patient-in, safety reporting, annual safety report, study completion and clinical study report)
As a SP-INV or Site-INV, ensure that the protection and safety of study participants always takes priority over any scientific or financial interest (e.g.the risk-benefit of the study, participant right, data protection such as data confidentiality and data coding & anonymization, the principles of ethics, ethical dilemma, and conflict of interest).
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
External Links
Swissmedic – see in particular
- Human medicines / Clinical trials
- Medical devices / Clinical trials
References
ICH GCP E6(R2) – see in particular article
- Art. 1.49 Definition regulatory authorities
HumRes: Coordination portal for human research in Switzerland
Swiss Law
ClinO – see in particular articles and annex
- Art. 23 Coordination and information in authorisation procedures
- Art. 30-34 Swissmedic Submission, Timelines and Approval Process including Studies with Radiation Source
- Annex 4 Application